FATE Q4 2018 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FATEFate Therapeutics, Inc.

$142M

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+61.7% YoY

Gross Profit

-$12M-748.6% margin

Operating Income

-$17M-1007.9% margin

Net Income

-$16M-964.9% margin

EPS (Diluted)

$-0.25

QoQ Revenue Growth

+61.9%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$12M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$213M

Total Liabilities

$53M

Stockholders' Equity

$160M

Cash & Equivalents

$191M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$1M	+61.7%
Gross Profit	-$12M	-$9M	-40.3%
Operating Income	-$17M	-$12M	-36.7%
Net Income	-$16M	-$12M	-28.2%